Report cover image

Idiopathic Inflammatory Myopathies

Publisher Reach Market Research
Published Jan 01, 2023
Length 27 Pages
SKU # RMR19136501

Description

MarketVue®: Idiopathic inflammatory myopathies (IIMs)

The MarketVue®: Idiopathic inflammatory myopathies market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Idiopathic inflammatory myopathies report is supported by 5 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Priovant
• CSL Behring
• Janssen
• argenx
• Alexion/AstraZeneca
• Pfizer
• Horizon Therapeutics
• Paean Biotechnology
• EMD Serono

Key drugs mentioned:
• IVIg (Octagam)
• Rituximab
• Azathioprine
• Methotrexate
• Mycophenolate mofetil
• Tofacitinib (Xeljanz)
• Etanercept (Enbrel)
• Adalimumab (Humira)
• Brepocitinib
• IgPro20
• Nipocalimab
• Efgartigimod (Vyvgart)
• Ravulizumab (Ultomiris)
• Zilucoplan (Zilbrysq)
• PF-06823859
• Daxdilimab
• PN-101
• M5049

Please note: the online download version of this report is for a global site license.

Table of Contents

27 Pages
1. DISEASE OVERVIEW
A heterogenous group of chronic, autoimmune disorders marked by inflammation and weakness of the skeletal muscle
Figure 1.1. Immune system involvement and druggable therapeutic targets in IIM
There are no standardized classification criteria for IIMs
Figure 1.2. Clinical manifestations in the IIM sub-types
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. Diagnosed prevalent cases of DM, ASyS, and IMNM by region
Table 2.1. Diagnosed prevalent and drug-treated patients in the US and EU5
3. DIAGNOSIS & CURRENT TREATMENT
Overview
Figure 3.1. Referral and diagnostic pathway for IIM patients
Autoantibody testing is useful in predicting the severity and disease course of IIM patients
Table 3.1. Clinical presentation of IIM subtypes and associated antibodies
All IIM patients need to be on drug therapy during the course of their disease
Table 3.2. Treatment goals for DM, ASyS, and IMNM patients
Figure 3.2. Physician-reported percentage of IIM patients receiving some form of drug therapy
Treatment flow for DM, ASyS, and IMNM
Immune suppression is the current backbone of IIM treatment
Figure 3.3. Current treatment share for DM, IMNM, and ASyS patients
Figure 3.4. Physician-reported rating of current therapy effectiveness in DM, IMNM, and ASyS
Upsides and downsides of current IIM treatments
Physicians’ perspectives on current treatment use in DM, ASyS, and IMNM
Octagam 10% is the only FDA-approved treatment for DM; there are no approved therapies for other subtypes
Table 3.3. Summary of the PRODERM trial results
IIMs are characterized by frequent occurrences of remission and relapse
Key treatment dynamics that will shape disease management and drug use in DM, ASyS, and IMNM
Figure 3.5. Important dynamics of IIM market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in DM, IMNM, and ASyS
Figure 4.2. Physician-reported unmet needs in DM, IMNM, and ASyS
There is a high unmet need for FDA-approved treatments with fewer insurance barriers
Figure 4.3. Neurologist-reported proportion of DM, IMNM, and ASyS who are not well-managed with current therapy options
Figure 4.4. Physician-reported proportion of DM, IMNM, and ASyS patients who encounter these barriers to receiving drug therapy
Physician perspectives on unmet needs in the diagnosis and treatment of IIM
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Percentage of rheumatologists and neurologists (n=26) rating target as “promising” for DM, IMNM, and ASyS (score of 6 or 7)
The pipeline for IIM is limited with three treatments in Phase 2/3 clinical development
Table 5.1. Comparison of ongoing Phase 3 and Phase 2/3 trials of therapies for IIM
The pipeline for DM is active; currently there are no industry-funded Phase 1 trials for IIM
Table 5.2. Comparison of ongoing Phase 2 therapies for IIM
Physician perspectives on novel, upcoming therapies are largely positive
6. VALUE & ACCESS
Overview
Table 6.1. Current IIM therapy pricing, U.S.
Table 6.2. Typical U.S. commercial payer coverage of Octagam 10%
Key market access dynamics that will continue to shape treatment use
Table 6.1. IIM patients by insurance type
7. METHODOLOGY
Primary market research approach
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us